| 8.02 -0.08 (-0.99%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.18 | 1-year : | 11.89 |
| Resists | First : | 8.72 | Second : | 10.18 |
| Pivot price | 7.4  |
|||
| Supports | First : | 6.9 |
Second : | 5.78 |
| MAs | MA(5) : | 7.92 |
MA(20) : | 7.39 |
| MA(100) : | 6.19 |
MA(250) : | 5.44 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 91.5 |
D(3) : | 88.1 |
| RSI | RSI(14): 59.6  |
|||
| 52-week | High : | 8.72 | Low : | 2.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLDB ] has closed below upper band by 17.4%. Bollinger Bands are 15.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.26 - 8.3 | 8.3 - 8.34 |
| Low: | 7.8 - 7.85 | 7.85 - 7.89 |
| Close: | 7.94 - 8.02 | 8.02 - 8.09 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Fri, 10 Apr 2026
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com
Fri, 10 Apr 2026
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Fri, 10 Apr 2026
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Tue, 07 Apr 2026
Solid Biosciences CEO speaks April 14; investor meetings follow - Stock Titan
Tue, 07 Apr 2026
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Wed, 25 Mar 2026
Solid Bio wins new buy at Guggenheim on lead asset - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 9,750 (K) |
| Shares Short P.Month | 9,430 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53.2 % |
| Return on Equity (ttm) | -109.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -156 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -4.04 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|